HER2 Biomarkers
News and reporting on HER2 biomarkers.
Vir Biotechnology Completes Licensing Deal With Sanofi for Three T-Cell Engager Programs
Vir gained exclusive worldwide rights to HER2-targeted, PSMA-targeted, and EGFR-targeted T-cell engager assets.
Relay Advancing Mutant PI3Kα Inhibitor into Phase III Breast Cancer Trial
The company said interim data from a Phase I trial of RLY-2608 plus fulvestrant support moving the program into a pivotal study in 2025.
Bayer Begins Phase III Trial of EGFR, HER2 Inhibitor in First-Line HER2-Mutant NSCLC
The firm will compare how BAY 2927088 impacts progression-free survival compared to Keytruda plus chemo in around 280 patients.
The firm has ongoing trials evaluating evorpacept with monoclonal antibodies, checkpoint inhibitors, and antibody-drug conjugates.
Lung Cancer Groups Seek Public Comment on Updated Biomarker Testing Guidelines
Updated guidelines recommend certain biomarker tests for early- and late-stage lung cancer at the time of diagnosis.